logo
Plus   Neg
Share
Email

Novartis: Aimovig Shows Long-term Efficacy In Treatment Of Episodic Migraine

Novartis (NVS) reported positive results from a 4.5-year, interim analysis of a 5-year, open-label treatment period to evaluate Aimovig in patients with episodic migraine. In the study, Aimovig reduced monthly migraine days, and also lowered the number of days requiring acute migraine-specific medication. The safety profile and tolerability were in line with previous clinical data for Aimovig.

Aimovig is a EMA and FDA-approved migraine prevention treatment. Novartis and Amgen are co-commercializing Aimovig in the US. Amgen has rights to Aimovig in Japan. Novartis has rights to commercialize in the rest of the world.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Justice has reached a settlement agreement with a Texas-based Taco Bell franchise owner for immigration-related discrimination against certain employees. The settlement resolves the DOJ's investigation into whether MUY Brands LLC, and a related management company, MUY Consulting Inc., violated the Immigration and Nationality Act. Starbucks is gearing up for the upcoming holiday season by introducing its 2019 holiday flavors in U.S. grocery stores. The launch of the coffee giant's holiday line-up this year includes returning holiday favorites as well as a new item. Customers can now take home products that are making a comeback such as Starbucks Holiday Blend K-Cup and Ground Coffee, Peppermint Mocha Flavored Ground Coffee, Peekay International issued a recall of 7 ounce and 14 ounce packs containing Keshav Dry Apricot food treats as they contain undeclared allergens such as sulfites, according to a statement published by The U.S. Food and Drug Administration. Consumption of the product by those allergic or having severe sensitivity to sulfites could run the risk of serious or life-threatening allergic reactions.
Follow RTT
>